Clinical Trial Diversity Requires Community-Based Research Infrastructure, US FDA’s Woodcock Says
Executive Summary
COVID-19 trials could have reached underserved populations better if research infrastructure was in place where people routinely get their health care, acting commissioner Janet Woodcock says; PhRMA is looking to establish a public-private partnership that would build a sustainable community-based infrastructure for clinical research.
You may also be interested in...
Clinical Trial Diversity: Data Points to Structural, Not Patient-Specific Solutions
Minorities are more likely to participate in cancer clinical trials than white people, but they are less likely to get the chance to say yes, highlighting the importance of bringing studies to different locations if sponsors are to be successful at increasing diversity.
Clinical Research Needs To Move ‘Out Of The Ivory Tower,’ FDA’s Woodcock Urges
Acting Commissioner says she is ‘really going to be pushing’ to have clinical trials conducted in the community. CDER’s Cavazzoni and CBER’s Marks discuss master protocols, decentralized trials, and real world evidence at DIA’s annual meeting.
Clinical Trial Diversity: We Must ‘Turn This Moment Into A Movement’
Pfizer and Genentech execs describe steps they’ve taken to increase diversity in clinical trials from moving trial sites into new neighborhoods to modifying protocols and holding others accountable for diversity.